Connect with us

Press Release

ADAMoracle—The First Decentralized Oracle That Supports Wide-area Node Quotation

Published

on

The birth of ADAMoracle

In the blockchain system, there are underlying service providers that provide vital nutrition to the main system, but are not easily noticed by the public, which is oracle. As a middleware connecting the blockchain system and real-world data, the oracle is a bridge that connects outside data with blockchain world and realizes the exchange of data and information .

With the large-scale application of blockchain technology in recent years, DeFi, NFT and other fields have shown a blowout development, and the market’s demand and requirements for underlying services are also constantly improving. However, the current major oracle products are still largely opaque, inaccurate, difficult to expand, and poorly resistant to attacks. Oracles that can truly meet market demand in an all-round way are extremely scarce.

Our Background Advantage

In order to meet the growing demand of the market, in July 2020, the ADAMoracle laboratory was officially established in the Emirate of Dubai, led by Ahmed Ebrahim, the founder and CEO of ADAMoracle, and the team led by CMO Christopher Quet and COO Olga Petrovska set out to create brilliant oracle products .

ADAMoracle has been favored by a large number of capital and institutions at the beginning of the establishment of the project. So far, ADAMoracle has obtained Collinstar, Redline Capital, CoinBene Labs, BTXCapital, 7O’Clock Foundation, MCS Capital, ChainUP Capital, ZB Labs ,Chain Capital and other dozens of institutions have strategic investment of USD 2 million.

ADAMoracle builds Web3.0 distributed wide-area node computing oracle network

In the Web3.0 blockchain network era, a complete middle-tier infrastructure will promote the next stage of the growth engine of the blockchain. However, the performance of the oracle network currently on the market and the cumbersomeness of building applications have discouraged many DeFi DApps. ADAMoracle is committed to changing the current status quo and completing a truly decentralized oracle network.

Web 3.0 developers can use ADAMoracle to implement a decentralized computing network with cross-chain support for multi-node computing. For the DeFi application market, customers connect to ADAMoracle through smart contracts to obtain prices, and obtain more accurate and secure quotations through multi-node connection quotations. At the same time, data is automatically distributed and stored. Each price feed will better verify the degree of decentralization, data accuracy, stronger stability and safety, and scalability of ADAMoracle.

Major features of ADAMoracle system

High security: ADAMoracle avoids a single point of failure by connecting multiple nodes to calculate and verify the quotation; the both way quotation and price verification prevent ADAMoracle from related attacks and further losses to customers;

Decentralization (high participation): ADAMoracle can connect to multiple types of servers through the global node to become bidders and verifiers, and participate in the oracle price generation. Many members can participate in the future development route of ADAMoracle;

High scalability: ADAMoracle supports more cross-chain DeFi DApps applications based on Polkadot, OKExChain, and BSC, compatible with many blockchain technology development frameworks, and builds a Defi application ecosystem in a friendly collaboration with developers;

High accuracy: with an oracle performance evaluation system, the deviation between the quotation per minute and the market price is accurate to 0.0012, it is very accuracy quotation system.

Low threshold: ADAMoracle can be connected to multiple types of servers, which greatly reduces maintenance and operation costs and achieves a quotation system platform that everyone can participate in.

The operation flow of ADAMoracle is as shown in the figure above. Customer release request–ADAMOracle Saas System releases the request contract after receiving it–System picking up nodes–Wide area node quotation–Aggregation of data provided by wide area node data providers–receving accurate Results–feedback to customers.

This process includes the three roles of data aggregator, node computing provider, and storage service provider in the ADAMoracle operation flow.

ADAMoracle data aggregator:

Data aggregators obtain key data from multiple exchanges (for example: OKEx, Coinbase, Huobi, Binance, etc.), and transmit the most reliable data to the ecosystem, thereby providing safe and reliable prices for the DeFi protocol Data, truly realize the decentralization of ADAMoracle data source and ensure the openness and transparency of data;

Node Computing provider:

As the first decentralized oracle that supports wide-area node quotation, the data service on the ADAMoracle chain has the advantage of high security and low threshold. The ADAMoracle has created a grand node service network, which can accommodate thousands of service providers for data verification and quotation services at the same time, which not only ensures the accuracy and credibility of the data, but also improves the anti-attack of the oracle itself. Lower the threshold for participation. Any enterprise or individual that has certain basic server equipment, has certain technical operation and maintenance capabilities, and can start nodes to complete Docker images, can join the ADAMoracle ecosystem and share the token ADAM dividend.

ADAMoracle has 33 global nodes and 66 backup nodes worldwide, and the global node can create its own mining pool in the future to connect thousands of multiple types of servers for secure distributed quotation, and the distributed quotation system is effective, This avoids the occurrence of a single point of failure, and provides a safer and more reliable quotation service for corporate customers.

Storage Service Provider

ADAMoracle not only implements a wide-area distributed quotation system under the multi-node computing network, but also securely distributes the generated on-chain/off-chain data to the blockchain storage system to prevent data loss. The decentralized oracle network is committed to the fact that every mining machine can become a offerer and verifier, participate in the oracle price quotation, and jointly govern and decide the future development route of ADAMoracle.

Summary:The ADAMoracle wide-area node computing network oracle architecture realizes unbounded interstellar network computing, so that each multi-type server can realize automated quotation, and has a safe rating function to ensure the accuracy of the price and better guarantee the oracle. The network’s decentralization characteristics and availability performance make it possible to have both fish and bear’s paws. ADAMoracle will attract more excellent developers to create excellent DeFi DApps applications. These new business paradigms of Web3.0 will also become a new form of economic society and organization in the future.

Our Economic Advantages

ADAMoracle for sustainable long-term development

Different from Bitcoin, ADAMoracle is not only a “green project” with decentralized energy resources, but also an infrastructure service facility that serves the majority of DeFi ecological projects. That is to say, the value of the ADAMoracle is not limited to the consensus of its own users. It will also generate actual value as the industry grows and develops. In the future, the ADAMoracle will support OKExchain, ETH, BSC, HECO, Polkadot and other public chains to further expand the ecology and promote the development of rich business formats such as lending, asset synthesis, and prediction markets.

ADAMoracle is a project that seeks long-term and stable development. It is based on the DeFi ecosystem, focuses on the entire blockchain system, and focuses on providing smart contract developers with comprehensive tools and data. ADAM is ADAMoracle’s contribution reward token to participants. It is the core value of the ecosystem. Its value comes from the value contribution of ecological members. The total issuance of ADAM is 100 million.

There are several ways to obtain ADAM tokens:

1. Participate in mining to obtain

50% of ADAM tokens are produced by mining, which is one of the main ways to obtain ADAM. Users can obtain ADAM token rewards by participating in pledge or liquidity mining;

2. Participate the ADAMoracle architecture

At present, the ADAMoracle has officially started the recruitment of global nodes, and many storage nodes will be recruited in the future. As a member of the ADAMoracle ecosystem, you can not only share the ADAMoracle development dividends, but also share the handling fees paid by the data demander. Currently, many Dapp projects have rigid data requirements. When they issue data requests to the ADAMoracle oracle machine, they need to pay ADAM as a handling fee. The node computing provider can obtain the corresponding ADAM by providing accurate quotation for the data demander; Aggregators and storage service providers can also get a corresponding share.

3.Participate to build up ADAMoracle ecological

ADAMoracle is a project that adopts decentralized community voting governance. The higher the value contribution of ecological members, the more ADAM token incentives will be obtained.

In the future, we will also establish “ADAMoracle Labs”, aiming to establish an open decentralized financial ecosystem based on the oracle protocol, and use the advantages of encrypted economic incentives to obtain and verify data. Allow the majority of ecological participants to better participate in our ecological construction, expand ecological application scenarios, form an ecological closed loop, and share and use financial digital asset data.

In general, the ADAMoracle creates a continuous positive incentive. The more users there are, the more fees will be generated; the more ecological participants, the higher the value of ADAM itself. At the same time, the increase in the value of ADAM is more conducive to the adoption of ADAMoracle oracles. Like Bitcoin, miners will compete to dig blocks for Token rewards to form a virtuous circle.

Looking around at the current high-quality oracle projects in the market, there are not a few that have a market value of over 100 million US dollars. Behind the prosperity that the total market value of cryptocurrencies exceeded US$2.5 trillion, there are countless groups who have quietly dedicated themselves to them. They do not take the model hotspot as a paradigm, but are rooted in the most basic field of the industry and empower the industry to flourish. They will never Forgotten by people.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders

Published

on

Dubai, United Arab Emirates, 13th Mar 2026 – ForexBrokers.Live is changing the way traders approach MetaTrader 4 (MT4) and MetaTrader 5 (MT5) platforms. The platform provides forex traders with essential tools, expert insights, and comprehensive guides to make informed decisions when choosing between these popular trading platforms.

MT4 has long been the go-to platform for forex traders, valued for its simplicity and reliability. Meanwhile, MT5 takes trading to the next level, offering additional features for more advanced traders, such as access to a wider range of financial instruments and enhanced charting capabilities. ForexBrokers.Live is committed to helping traders understand these platforms and how they can be used to maximize success in the forex market.

Empowering Traders with Knowledge

ForexBrokers.Live provides easy-to-understand guides that break down the complexities of both MT4 and MT5. The platform doesn’t just explain how to download and set up these platforms, it also offers expert reviews, broker comparisons, and practical tips on using advanced tools effectively. Whether you’re a beginner or an experienced trader, ForexBrokers.Live ensures you have the resources to choose the right broker and platform.

Choosing the Right Broker

Selecting the right broker is as important as choosing the right platform. ForexBrokers.Live makes this process easier by comparing brokers that support MT4 and MT5, highlighting their unique features, spreads, execution speeds, and customer support. This helps traders find the best-suited broker for their needs.

The platform goes beyond platform usage to offer in-depth broker reviews, ensuring traders are well-equipped to navigate the forex market confidently. ForexBrokers.Live also regularly updates its content, so users always have the latest information on brokers and platform features.

Looking Forward

ForexBrokers.Live continues to evolve to meet the growing needs of the trading community. The platform plans to expand its content with more detailed guides, updated reviews, and new features designed to keep traders informed and ready for the market’s challenges.

About ForexBrokers.Live

ForexBrokers.Live is a dedicated resource for forex traders, offering comprehensive guides, expert reviews, and broker comparisons for MetaTrader 4 (MT4) and MetaTrader 5 (MT5). With a focus on clarity and practicality, ForexBrokers.Live helps traders of all levels make informed decisions and choose the best platforms and brokers for their needs.

Media Contact

Organization: ForexBrokers.Live

Contact Person: Manish

Website: https://forexbrokers.live

Email: Send Email

City: Dubai

Country:United Arab Emirates

Release id:42570

The post ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC

Published

on

Export, PA, United States, 13th Mar 2026 – The upcoming episode of Now We Know! with Steve Guttenberg, airing March 14, 2026 at 1pm ET on CNBC will feature FS-Elliott, a company specializing in the design and manufacturing of high-performance centrifugal air and gas compressors.

The segment provides viewers with a behind-the-scenes look at the engineering and precision required to produce industrial equipment that supports manufacturing, energy production, and critical infrastructure worldwide. Through advanced technology and meticulous design, FS-Elliott’s compressors help power operations across a wide range of industries.

From reliability and efficiency to long-term performance, the episode highlights the role that specialized equipment plays in keeping industrial systems running smoothly.

By showcasing FS-Elliott’s work, Now We Know! sheds light on the often-unseen technologies that support modern industry. The series continues its mission to reveal the innovation and expertise behind the systems that drive everyday life.

About Now We Know!

Hosted by actor, author, and businessman, Steve Guttenberg, this unique platform inspires the next generation of knowledge seekers and viewers around the country. Each episode features up to four industry experts who provide their own unique perspective on the topic at hand via a 6-8–minute segment produced by our team, bringing a fresh look at interesting narratives, moderated by the one and only Steve Guttenberg. 

Learn more at NowWeKnowTV.com

About FS-Elliott Co., LLC

FS-Elliott is a global leader in the engineering and manufacturing of oil-free, centrifugal air and gas compressors, with operations in over 90 countries. For over 60 years, FS-Elliott has combined a commitment to quality with advanced technology, enabling our customers to increase productivity and lower system operating costs. For more information, visit www.fs-elliott.com.

For more details, contact:

Now We Know! with Steve Guttenberg

(877) 546-9995

feature@nowweknowtv.com

nowweknowtv.com

SOURCE Now We Know! with Steve Guttenberg

All images courtesy of Now We Know! with Steve Guttenberg

 

Media Contact

Organization: Now We Know!with Steve Guttenberg

Contact Person: Media Relations

Website: https://nowweknowtv.com/

Email: Send Email

Contact Number: +18775469995

City: Export

State: PA

Country:United States

Release id:42579

The post FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.

More information about Desidustat Tablets and Renal Anaemia

As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.

Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.

The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015

3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)

4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST